Bristol Pravachol Ads Cited In Missouri AG Investigation, Class Action Lawsuit
This article was originally published in The Pink Sheet Daily
Executive Summary
The DTC campaign misled consumers into purchasing pravastatin, the proposed class action complaint says. FDA challenged the claim that Pravachol would help prevent stroke in patients without heart disease in an August 2003 warning letter.
You may also be interested in...
Bristol Sends Pravachol Corrective Letter To Statin Prescribers, Patients
Bristol takes out full-page corrective newspaper ads clarifying Pravachol’s indication. The ad also references the approval of Merck’s Zocor, which carries the same indication as Pravachol.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.